The future of adjuvant therapy in ampullary cancer: should we offer it to our patients?

Sri Harsha Tella, Amit Mahipal


Ampullary carcinoma is a relatively rare and heterogenous neoplasm accounting for 0.2% of all gastrointestinal tract malignancies. The data from National Cancer Institute’s Surveillance, Epidemiology, and End Results Program have shown an increase in incidence of ampullary cancer over the last decade (1).

Article Options

Download Citation